ACADIA PHARMACEUTICALS INC (ACAD)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$119.2M
Cash & Equivalents
$34.0M
Quarterly Burn Rate
$4,490M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
TROFINETIDE
DAYBUE STIX |
APPROVED | Acute Postoperative Pain, Adjunctive Treatment of Major Depressive Disorder, Agitation and Aggression in Alzheimer's Disease, Alzheimer's Disease Psychosis, Autism Spectrum Disorder, Bunionectomy, Delusion, Dementia-related Psychosis, Depressive Disorder, Treatment-Resistant, Hallucinations, Hyperphagia in Prader-Willi Syndrome, Insomnia Chronic, Intermittent Explosive Disorder, Irritability Associated With Autism Spectrum Disorder, Lewy Body Dementia Psychosis, Major Depressive Disorder (MDD), Neurodegenerative Diseases, Neuropsychiatric Symptoms Related to Neurodegenerative Disease, Osteoarthritis Pain, Parkinson Disease, Parkinson Disease Psychosis, Parkinson's Disease, Parkinson's Disease Psychosis, Posttraumatic Stress Disorder, Psychoses, Psychosis, Rett Syndrome, Schizophrenia, Treatment of Depression in Adults With Parkinson's Disease (PD) |
|
PIMAVANSERIN TARTRATE
NUPLAZID |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-31 | Phase2 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
Active Clinical Trials (10)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05357612 | Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Disease... | PHASE4 | Recruiting | 75 |
| NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | PHASE3 | Recruiting | 1,074 |
| NCT06173531 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | PHASE3 | Active Not Recruiting | 170 |
| NCT06194799 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | PHASE3 | Enrolling By Invitation | 752 |
| NCT07095465 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | PHASE3 | Enrolling By Invitation | 126 |
| NCT06420297 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | PHASE3 | Enrolling By Invitation | 160 |
| NCT07029581 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | PHASE2 | Recruiting | 180 |
| NCT07284667 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | PHASE2 | Recruiting | 153 |
| NCT05895513 | Pimavanserin and Aggression and Social Cognition. | PHASE2 | Recruiting | 35 |
| NCT05999240 | Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder | PHASE2 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.